Helus Pharma announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its expertise in biotechnology, drug delivery, and central nervous system clinical development. The additions support Helus Pharma’s focus on disciplined, evidence-based drug development for programs targeting major depressive disorder and generalized anxiety disorder, addressing unmet needs in mental health.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s proprietary NSAs are intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through NSAs providing durable improvements in mental health.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. The company has an extensive research portfolio of investigational NSAs. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1111024042/Biomednewsbreaks-Helus-PharmaTM-NASDAQ-HELP-Cboe-CA-HELP-Adds-Robert-Langer-Stephen-Brannan-To-Scientific-Advisory-Board